E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10010331 |
E.1.2 | Term | Congenital, familial and genetic disorders |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Part A: to evaluate the PK of LUM and IVA and their metabolites Part B: to evaluate the safety of LUM/IVA |
|
E.2.2 | Secondary objectives of the trial |
Part A: To evaluate the safety of LUM/IVA Part B: To evaluate the PD of LUM/IVA |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Subjects who weigh ≥8 kilogram (kg) without shoes and wearing light clothing at the Screening Visit - Subjects with confirmed diagnosis of CF at the Screening Visit - Subjects who are homozygous for the F508del Cystic fibrosis transmembrane conductance regulator (CFTR) mutation
|
|
E.4 | Principal exclusion criteria |
- Any clinically significant laboratory abnormalities at the Screening Visit that would interfere with the study assessments or pose an undue risk for the subject - An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 28 days before Day 1 - A standard 12 lead ECG demonstrating QTc >450 millisecond (msec) at the Screening Visit. - History of solid organ or hematological transplantation. - Ongoing or prior participation in an investigational drug study (including studies investigating LUM and/or IVA) within 30 days of the Screening Visit. - History of cataract/lens opacity or evidence of cataract/lens opacity determined to be clinically significant by a licensed ophthalmologist during the ophthalmologic examination at the Screening Visit |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Part A: Pharmacokinetic (PK) parameters of lumacaftor (LUM) and ivacaftor (IVA): estimated peak concentrations (Cmax) - Part A: Pharmacokinetic (PK) parameters of lumacaftor (LUM) and ivacaftor (IVA): estimated trough concentrations (Ctrough) - Part B: Safety and Tolerability assessments as determined by number of subjects with adverse events (AEs) and serious adverse events (SAEs)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Part A: up to 15 Days Part B: Baseline up to 28 days after last dose (up to 28 weeks) |
|
E.5.2 | Secondary end point(s) |
- Part A: PK parameters of LUM and IVA metabolites: estimated peak concentrations (Cmax) of lumacaftor and ivacaftor metabolites - Part A: PK parameters of LUM and IVA metabolites: estimated trough concentrations (Ctrough) of lumacaftor and ivacaftor metabolites - Part A: Safety and Tolerability assessments as determined by number of subjects with adverse events (AEs) and serious adverse events (SAEs) - Part B: Absolute change from baseline in sweat chloride level - Part B: Absolute change from baseline in body mass index (BMI) and BMI for age z score
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Part A: up to 15 days Part A (safety): up to 10 +/- 3 days after the last dose (up to 25 +/- 3 days) Part B: Week 24 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 26 |